Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Overview
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Companies Involved in Therapeutics Development
Basilea Pharmaceutica Ltd
BioPlx Microbiomics Pvt Ltd
Debiopharm Intertiol SA
Destiny Pharma Plc
Galenus Therapeutics Inc
HyPharm GmbH
LegoChem Biosciences Inc
icons Srl
Sealife PHARMA GMBH
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drug Profiles
afabicin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01KS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioPlx-01WT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceftobiprole medocaril - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GTX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HY-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-010699 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
I-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0904 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit D Gyrase and D Topoisomerase IV for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
targocil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Product Development Milestones
Featured News & Press Releases
Apr 20, 2018: Basilea reports presentations of ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Apr 12, 2018: Cardiome Presents Zevtera Abstracts at ECCMID 2018
Apr 21, 2017: Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Basilea Pharmaceutica Ltd, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by BioPlx Microbiomics Pvt Ltd, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Debiopharm International SA, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Destiny Pharma Plc, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Galenus Therapeutics Inc, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by HyPharm GmbH, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by LegoChem Biosciences Inc, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Naicons Srl, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Pipeline by Sealife PHARMA GMBH, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Dormant Projects, H2 2020
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Discontinued Products, H2 2020